Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice
Previous results in the laboratory of the authors showed that Saccharomyces cerevisiae strain 905, isolated during ‘cachaça’ production, was able to colonize and survive in the gastrointestinal tract of germ-free and conventional mice, and to protect these animals against oral challenge with Salmonella enterica serotype Typhimurium or Clostridium difficile. In the present work, the effects of S. cerevisiae 905 on the translocation of Salm. Typhimurium (mesenteric lymph nodes, Peyer's patches, spleen, liver) as well as on the immune system (number of Küpffer cells, immunoglobulin production, clearance of Escherichia coli B41) were evaluated in gnotobiotic and/or conventional mice. The treatment with the yeast reduced significantly the translocation of Salm. Typhimurium to liver in gnotobiotic animals and to all the organs tested in conventional mice. The number of Küpffer cells per 100 hepatocytes in liver was significantly higher (P<0.05) in yeast mono-associated mice (52.9±15.7) than in germ-free controls (38.1±9.0). Probably as a consequence, clearance of E. coli B41 from the bloodstream was more efficient in yeast mono-associated animals when compared to germ-free mice. Higher levels (P<0.05) of secretory IgA in intestinal content and of IgA and IgM in serum were observed in yeast mono-associated mice when compared to germ-free group. Concluding, the protection against pathogenic bacteria observed in a previous study was probably due to a modulation of both local and systemic immunity of mice treated with S. cerevisiae 905.
BrandãoR. L.,
CastroI. M.,
BambirraE. A.,
AmaralS. C.,
FiettoL. G.,
TropiaM. J. M.,
NevesM. J.,
Dos SantosR. G.,
GomesN. C. M.,
NicoliJ. R.1998; Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae
. Appl Environ Microbiol 64:564–568
ButsJ. P.,
BernasconiP.,
VaermanJ. P.,
DiveC.1990; Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii
. Dig Dis Sci 35:251–256[CrossRef]
CastagliuoloI.,
RieglerM. F.,
ValenickL.,
LamontJ. T.,
PothoulakisC.1999; Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67:302–307
FiettoJ. L. R.,
AraújoR. S.,
ValadãoF. N.,
FiettoL. G.,
BrandãoR. L.,
NevesM. J.,
GomesC. O.,
NicoliJ. R.,
CastroI. M.2004; Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii
. Can J Microbiol 50:615–621[CrossRef]
Food and Agriculture Organization of the United Nations & World Health Organization2002; Guidelines for the Evaluation of Probiotics in Food , Food and Agriculture Organization of the United Nations and World Health Organization Working Group Report. London, Ontario, Canada: April 30–May 1 2002
GregoryS. H.,
SagnimeniA. J.,
WingE. J.1996; Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J Immunol 157:2514–2520
GedekB. R.1999; Adherence of Escherichia coli serogroup O157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii
. Mycoses 42:261–264[CrossRef]
HajishengallisG.,
NikolovaE.,
RusselM. W.1992; Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A antibodies to the cell surface protein antigen I/II: reversal by IgA 1 protease cleavage. Infect Immun 60:5057–5064
HamuroJ.,
AkiyamaY.,
IguchiY.,
IsawaM.,
MatsuoT.1982; Distinct roles of serum factors induced by a T cell specific immune adjuvant lentinan in cellular immune responses. Int J Immunopharmacol 4:268
HerekO.,
KaraI. G.,
KaleliI.2004; Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury. Surg Today 34:256–260[CrossRef]
HirakataY.,
TomonoK.,
TatedaK.,
MatsumotoT.,
FuruyaN.,
ShimoguchiK.,
KakuM.,
YamaguchiK.1991; Role of bacterial association with Küpffer cells in occurrence of endogenous systemic bacteremia. Infect Immun 59:289–294
JahnH. U.,
UllrichR.,
SchneiderT.,
LiehrR. M.,
SchieferdeckerH. L.,
HolstH.,
ZeitzM.1996; Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 57:95–104[CrossRef]
KovacsD. J.,
BerkT.2000; Recurrent Clostridium difficile -associated diarrhea and colitis treated with Saccharomyces cerevisiae (baker's yeast) in combination with antibiotic therapy: a case report. J Am Board Farm Pract 13:138–140[CrossRef]
MartinsF. S.,
NardiR. M. D.,
ArantesR. M. E.,
RosaC. A.,
NevesM. J.,
NicoliJ. R.2005; Screening of yeast as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol 51:83–92[CrossRef]
McFarlandL. V.,
SurawiczC. M.,
GreenbergR. N.,
ElmerG. W.,
MoyerK. A.,
MelcherS. A.,
BowenK. E.,
CoxJ. L.1995; Prevention of β -lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90:439–448
MoreauM. C.,
RaibaudP.,
MullerM. C.1982; Relation entre le développement du systéme immunitaire intestinal à IgA et l'établissement de la flore microbienne dans le tube digestif de souris holoxênique. Ann Inst Pasteur Immunol 133B:29–39
NeumannE.,
OliveiraM. A. P.,
CabralC. M.,
MouraL. N.,
NicoliJ. R.,
VieiraE. C.,
CaraD. C.,
PodoprigoraG. I.,
VieiraL. Q.1998; Monoassociation with Lactobacillus acidophilus UFV-H2B20 stimulates the phagocytic system of germ-free mice. Br J Med Biol Res 31:1565–1573[CrossRef]
PeretL. A.,
PennaF. J.,
BambirraE. A.,
NicoliJ. R.1998; Dose effect of oral Saccharomyces boulardii treatments on morbidity and mortality in immunosuppressed mice. J Med Microbiol 47:111–116[CrossRef]
RodriguesA. C.,
NardiR. M.,
BambirraE. A.,
VieiraE. C.,
NicoliJ. R.1996; Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 81:251–256[CrossRef]
RodriguesA. C.,
CaraD. C.,
FretezS. H. G. G.,
CunhaF. Q.,
VieiraE. C.,
NicoliJ. R.,
VieiraL. Q.2000; Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89:404–414[CrossRef]
SilvaA. M.,
BarbosaF. H. F.,
DuarteR.,
VieiraL. Q.,
ArantesR. M. E.,
NicoliJ. R.2004; Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice. J Appl Microbiol 97:29–37[CrossRef]
SurawiczC. M.2003; Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 17:775–783[CrossRef]
SurawiczC. M.,
McFarlandL. V.,
GreenbergR. N.,
RubinM.,
FeketyR.,
MulliganM. E.,
GarciaR. J.,
BrandmarkerS.,
BowenK.other authors2000; The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii
. Clin Infect Dis 31:1012–1017[CrossRef]
Van der Aa KühleA.,
SkovgaardK.,
JespersenL.2005; In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. Int J Food Microbiol 101:29–39[CrossRef]
Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice